RRP9 promotes gemcitabine resistance in pancreatic cancer via activating AKT signaling pathway

Zhiqi Zhang,Haitao Yu,Wenyan Yao,Na Zhu,Ran Miao,Zhiquan Liu,Xuwei Song,Chunhua Xue,Cheng Cai,Ming Cheng,Ke Lin,Dachuan Qi
DOI: https://doi.org/10.1186/s12964-022-00974-5
IF: 7.525
2022-11-26
Cell Communication and Signaling
Abstract:Pancreatic cancer (PC) is a highly lethal malignancy regarding digestive system, which is the fourth leading factor of cancer-related mortalities in the globe. Prognosis is poor due to diagnosis at advanced disease stage, low rates of surgical resection, and resistance to traditional radiotherapy and chemotherapy. In order to develop novel therapeutic strategies, further elucidation of the molecular mechanisms underlying PC chemoresistance is required. Ribosomal RNA biogenesis has been implicated in tumorigenesis. Small nucleolar RNAs (snoRNAs) is responsible for post-transcriptional modifications of ribosomal RNAs during biogenesis, which have been identified as potential markers of various cancers. Here, we investigate the U3 snoRNA-associated protein RRP9/U3-55 K along with its role in the development of PC and gemcitabine resistance.
cell biology
What problem does this paper attempt to address?